Stifel Nicolaus Cuts Medtronic (NYSE:MDT) Price Target to $95.00

Medtronic (NYSE:MDT) had its price objective dropped by research analysts at Stifel Nicolaus from $105.00 to $95.00 in a research note issued to investors on Monday,MarketScreener reports. The firm presently has a “hold” rating on the medical technology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 11.09% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Barclays lifted their target price on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Needham & Company LLC restated a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Citigroup dropped their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, CICC Research started coverage on Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.10.

Medtronic Stock Down 0.9%

Medtronic stock opened at $85.52 on Monday. The company’s 50 day simple moving average is $94.18 and its 200 day simple moving average is $96.19. The firm has a market capitalization of $109.80 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 2.24 and a beta of 0.75. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic will post 5.46 EPS for the current year.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Institutional investors have recently bought and sold shares of the stock. Purpose Unlimited Inc. purchased a new stake in shares of Medtronic during the fourth quarter valued at approximately $8,182,000. Rockefeller Capital Management L.P. lifted its position in Medtronic by 19.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 719,949 shares of the medical technology company’s stock valued at $69,159,000 after acquiring an additional 118,110 shares in the last quarter. World Investment Advisors increased its holdings in shares of Medtronic by 5.7% in the 4th quarter. World Investment Advisors now owns 167,403 shares of the medical technology company’s stock worth $16,081,000 after purchasing an additional 8,961 shares in the last quarter. Winthrop Partners WNY LLC purchased a new position in shares of Medtronic in the fourth quarter worth $1,223,000. Finally, Meadowbrook Advisors Group LLC bought a new position in shares of Medtronic during the fourth quarter valued at $2,156,000. 82.06% of the stock is owned by institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).